

Company announcement no 19/2021

## Interim Report Q3 2021

EBITDA fixed herd prices (FHP) for Q3 2021 increased to 7,536 mEUR (Q3 2020: 7,253 kEUR), corresponding to an EBITDA margin FHP of 28.3% (Q3 2020: 29.3%). The quarterly EBITDA in Q3 2021 increased by 283 kEUR (compared to Q3 2020). Q3 harvest influenced EBITDA margin significantly, as it is EBITDA without revenue. Harvest EBITDA was Q3 2021 4.6 mEUR and Q3 2020 3.8 mEUR, EBITDA margin FHP (without harvest) was 10.9% (Q3 2019: 14.1%).

ASF outbreak in Ostrov impacted Q3 result negative with 518 kEUR being feed inventories in Feed Kitchen that needed to be scrapped (due to instructions from Authorities), which are not covered by insurance policy. Idavang expects that when Q4 report is released a full plan of when production will be established again.

Sales prices in Q3 were 1.18 EUR/kg live weight, up from 1.12 EUR/kg (Q3 2020). The price increase has been driven by better supply/demand relation in Russia.

The outlook is negative in EU/Lithuania as demand from China has decreased significantly, whereas Russia the demand is better than in 2020.



Feed prices in Q3 2021 were 255 EUR/T (compared to 230 EUR/T Q3 2020). A significant amount of grain is hedged until harvest 2022 either in storage, on fields, or contracts, reducing future increases in feed price, as raw materials as grain have been increasing. End September 2021 4.0 mEUR hedging gains are included in Group equity in other reserves.

The herd valuation in Q3 decreased by 4,899 kEUR (compared to 30.06.2021). The decrease is driven on price pressure in EU due to over production of pork, as the export from EU to China currently is on a minimum, due to low prices in China.

Free cash flow was 2,637 kEUR in Q3 2021 (Q3 2020: 3.771 kEUR).

Net interest-bearing debt has decreased from 87,3 mEUR (31.12.2020) to 82,7 mEUR driven by cash flow from operating activities.

### Selected financial highlights and key ratios

EUR millions	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Total revenue	26.703	24.728	79.769	79.284	101.754
EBITDA	2.637	3.432	17.794	14.115	10.480
EBITDA margin	9,9%	13,9%	22,3%	17,8%	10,3%
EBITDA fixed herd price	7.536	7.253	15.398	19.258	19.744
EBITDA margin fixed herd price	28,2% 	29,3% 	19,3% 	24,3% 	19,4%
Net income	-46	-1.477	7.899	283	-7.761
Free cash flow	2.641	3.771	9.904	25.168	24.420
Net interest-bearing debt	82.653	63.995	82.653	63.995	87.346

### Further information

Bondholders - Claus Baltersen, CEO phone +370 (685) 34 104

Media - Jytte Rosenmaj, Board Member phone +45 26 73 46 99

### Finance Calendar 2021

28<sup>th</sup> Feb 2022: Annual Report 2021

### Forward-looking statements

This interim report contains “forward-looking statements.” Undue reliance should not be placed on forward-looking statements because they relate to and depend on circumstances that may or may not occur in the future, and actual results may differ materially from those in forward-looking statements. Forward-looking statements include, without limitation, statements regarding our business, financial circumstances, strategy, results of operations, financing and other plans, objectives, assumptions, expectations, prospects, beliefs and other future events and prospects. We undertake no obligation and do not intend to publicly update or revise any of these forward-looking statements unless prescribed by law or by stock exchange regulation.

## Table of contents

<b>REVIEW</b> .....	<b>4</b>
Financial Highlights and Key Ratios.....	4
Management's Review .....	5
Development in segments in Q3 2021 .....	6
Statement by the Board and the Executive Management.....	8
<b>FINANCIAL STATEMENT</b> .....	<b>9</b>
Income Statement .....	9
Statement of comprehensive income .....	9
Assets .....	10
Liabilities and Equity.....	10
Cash Flow Statement.....	11
Statement of changes in equity .....	12
Notes.....	13
Quarterly Financial Highlights and Key Ratios.....	18

## Review

### Financial Highlights and Key Ratios

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
<b>Income statement</b>					
Revenue	26.703	24.728	79.769	79.284	101.754
EBITDA	2.637	3.432	17.794	14.115	10.480
EBITDA fixed herd price	7.536	7.253	15.398	19.258	19.744
EBIT	786	1.648	12.340	8.522	2.781
Financial items, net	-1.539	-3.628	-4.257	-8.171	-11.224
Profit/(loss) for the period	-46	-1.477	7.899	283	-7.761
<b>Cash flow</b>					
Operating activity	-322	3.120	5.374	23.833	21.768
Investing activity	1.298	-739	-318	-2.751	-4.217
Financing activity	-5.611	-1.504	-12.119	-15.362	-5.996
Free cash flow	2.641	3.771	9.904	25.168	24.420
<b>Balance sheet</b>					
Non-current assets	94.257	97.979	94.257	97.979	97.353
Net working capital	20.501	11.883	20.501	11.883	11.079
Net operating assets	114.758	109.862	114.758	109.862	108.432
Total assets	149.962	167.393	149.962	167.393	146.369
Equity	44.659	54.211	44.659	54.211	29.868
Net interest bearing debt	82.653	63.995	82.653	63.995	87.346
<b>Key financials Group</b>					
EBITDA margin	9,9%	13,9%	22,3%	17,8%	10,3%
EBITDA margin - fixed herd prices	28,2%	29,3%	19,3%	24,3%	19,4%
Cash conversion - fixed herd prices	35%	52%	64%	131%	124%
NIBD / EBITDA fixed price LTM	5,2	2,5	5,2	2,5	4,4
Equity ratio	29,8%	32,4%	29,8%	32,4%	20,4%

## Management's Review

### Income statement

#### Revenue

The revenue for Q3 2021 was 26,703 kEUR (Q3 2020: 24,728 kEUR) up 8%. The higher sale is due to higher sales prices of 7% compared to Q3 2020 plus higher volume sold.

#### Value adjustment, biological assets

The herd valuation in Q3 decreased by 4,899 kEUR (compared to 30.06.2021). The decrease is driven on price pressure in EU due to over production of pork, as the export from EU to China currently is on a minimum, due to low prices in China.

#### EBITDA fixed herd prices (FHP)

EBITDA fixed herd prices (FHP) for Q3 2021 increased to 7,536 mEUR (Q3 2020: 7,253 kEUR), corresponding to an EBITDA margin FHP of 28.3% (Q3 2020: 29.3%). The quarterly EBITDA in Q3 2021 increased by 283 kEUR (compared to Q3 2020). Q3 harvest influenced EBITDA margin significantly, as it is EBITDA without revenue. Harvest EBITDA was Q3 2021 4.6 mEUR and Q3 2020 3.8 mEUR, EBITDA margin FHP (without harvest) was 10.9% (Q3 2019: 14.1%).

ASF outbreak in Ostrov impacted Q3 result negative with 518 kEUR being feed inventories in Feed Kitchen that needed to be scrapped (due to instructions from Authorities), which are not covered by insurance policy. Idavang expects that when Q4 report is released a full plan of when production will be established again.

Sales prices in Q3 were 1.18 EUR/kg live weight, up from 1.12 EUR/kg (Q3 2020). The price increase has been driven by better supply/demand relation in Russia.

Feed prices in Q3 2021 were 255 EUR/T (compared to 230 EUR/T Q3 2020). A significant amount of grain is hedged until harvest 2022 either in storage, on fields, or contracts, reducing future increases in feed price, as raw materials as grain have been increasing. End September 2021 4.0 mEUR hedging gains are included in Group equity in other reserves.

#### Net financials

The net interest expenses for Q3 2021 increase 275 kEUR to 1,664 kEUR (Q3 2020: 1,389 kEUR), bond cost is 83% of interest expenses.

Foreign exchange adjustments in Q3 2021 were positive with 125 kEUR (Q3 2020 -2.238 kEUR). The foreign exchange adjustments are driven mainly by currency fluctuations in intercompany debt (+107 kEUR Q3 2021) hence limited cash effect.

#### Balance Sheet

At 30<sup>th</sup> September 2021, Idavang's balance sheet amounted to 149,962 kEUR (December 2020: 146,219 kEUR).

Equity on 30<sup>th</sup> September 2021 amounted to EUR 44.7m at an equity ratio of 29,8%.

Net interest-bearing debt has decreased from 87,3 mEUR (31.12.2020) to 82,7 mEUR driven by cash flow from operating

The networking capital increased to 20,501 kEUR (from 11,079 kEUR 31.12.2020). The increase of 9,422 kEUR is mainly due to value adjustment on herd displacement of 2.397 kEUR and higher inventories 4.001 kEUR partly due to higher prices.

#### Cash flow

Cash flow from ordinary activities for Q3 2021 decreased to -323 kEUR (Q3 2020: 3.120 kEUR). The decrease of 3,443 kEUR consists mainly of two factors: Hedging gains in Q3 2021 are 2.207 kEUR higher than Q3 2020 (with 2.461 kEUR) and the value of harvest is 679 kEUR higher (compared to Q2 2020 with 7.613 kEUR).

#### Events after the balance sheet date

- No events after the balance sheet date



## Development in segments in Q3 2021

### Lithuania

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Revenue	13.728	13.396	42.180	48.237	60.551
Value adjustment, biological assets	-4.359	-4.092	710	-8.332	-11.270
Production costs	-14.820	-12.879	-42.050	-39.255	-53.098
Administrative costs	-425	-429	-1.317	-1.325	-1.844
Other income	1.129	458	1.770	1.407	1.615
Other expense	11	-	333	-2	2
<b>Operating profit</b>	<b>-4.736</b>	<b>-3.545</b>	<b>1.627</b>	<b>730</b>	<b>-4.044</b>
Net Financials	-292	-208	-897	-698	-1.056
Foreign exchange adjustments	-	-	-	-	-
<b>Profit before tax</b>	<b>-5.028</b>	<b>-3.753</b>	<b>731</b>	<b>32</b>	<b>-5.100</b>
Tax on profit for the year	745	502	-123	-24	765
<b>Profit for the period</b>	<b>-4.284</b>	<b>-3.251</b>	<b>608</b>	<b>8</b>	<b>-4.335</b>

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Depreciations included in production cost	-714	-761	-2.196	-2.226	-3.182
<b>EBITDA</b>	<b>-4.023</b>	<b>-2.784</b>	<b>3.824</b>	<b>2.956</b>	<b>-862</b>
<i>EBITDA fixed herd prices</i>	<i>337</i>	<i>1.309</i>	<i>3.113</i>	<i>11.288</i>	<i>10.408</i>

Lithuania accounted for 51 % of Group revenue in Q3 2021 (Q3 2020: 54 %).

The EBITDA fixed herd price for Q3 2021 amounted to 337 kEUR, corresponding to an EBITDA margin of 2.5% (Q3 2020: 1.309 kEUR and EBITDA margin 9.8 %). The EBITDA decreased compared to Q3 2020 by 972 kEUR mainly feed -859 kEUR (price effect 684 kEUR/FCR 175 kEUR), whereas price effect of slaughter pigs effect -406 kEUR and other income was 671 kEUR higher (as 839 kEUR was received in covid subsidy).

The sales price decreased 3 % compared to Q3 2020 to an average of 1,02 EUR per kilo slaughter pigs' live weight in Q3 2021 (Q3 2020: 1,05 EUR per kilo live weight slaughter pigs) with 406 kEUR negative effect.



## Russia

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Revenue	12.975	11.331	37.588	31.046	41.203
Value adjustment, biological assets	-540	271	1.686	3.190	2.006
Production costs	-6.405	-5.972	-27.433	-25.405	-35.516
Administrative costs	-377	-274	-963	-869	-1.038
Other income	492	38	726	375	821
Other expense	-518	-10	-518	-53	-67
<b>Operating profit</b>	<b>5.627</b>	<b>5.383</b>	<b>11.087</b>	<b>8.284</b>	<b>7.409</b>
Net Financials	-399	-350	-1.061	-1.053	-1.444
Foreign exchange adjustments	18	-158	-15	-229	-128
<b>Profit before tax</b>	<b>5.247</b>	<b>4.875</b>	<b>10.011</b>	<b>7.003</b>	<b>5.837</b>
Tax on profit for the year	-38	2	-62	-44	-83
<b>Profit for the period</b>	<b>5.209</b>	<b>4.877</b>	<b>9.949</b>	<b>6.958</b>	<b>5.754</b>

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Depreciations included in production cost	-1.138	-1.023	-3.257	-3.364	-4.514
<b>EBITDA</b>	<b>6.765</b>	<b>6.406</b>	<b>14.345</b>	<b>11.649</b>	<b>11.923</b>
<i>EBITDA fixed herd prices</i>	<i>7.305</i>	<i>6.135</i>	<i>12.658</i>	<i>8.459</i>	<i>9.917</i>

Russia accounted for 49 % of Group revenue in Q3 2021 (Q3 2020: 46 %).


The EBITDA fixed herd price for Q3 2021 amounted to 7,305 kEUR, corresponding to an EBITDA margin of 56.4 % (Q3 2020: 6,135 kEUR and EBITDA margin 54.1 %), an increase of 1.170 kEUR. Development in EBITDA effected by a number of factors positive being sales price increased 1.880 kEUR and better harvest 860 kEUR, whereas negative ones being increasing feed prices -991 kEUR effect and utilization of materials in feed kitchen in Ostrov -518 kEUR (not covered by insurance policy).

Q3 harvest influenced EBITDA margin significantly, as it is EBITDA without revenue, hence EBITDA margin FHP (without harvest) was 20.7% (Q3 2020: 20.8%).

ASF outbreak in Ostrov impacted Q3 result negative with 518 kEUR being feed inventories in Feed Kitchen that needed to be scrapped (due to instructions from Authorities), which are not covered by insurance policy. Idavang expects that when Q4 report is released a full plan of when production will be established again.

Harvest EBITDA was 860 kEUR higher in Q3 2021 (4,636 kEUR compared to 3,776 kEUR Q3 2020). The harvest EBITDA was affected by average yields, but with higher prices than 2020 on especially rape.

The sales price increased 17 % compared to Q3 2020 to an average of 1,42 EUR per kilo slaughter pigs' live weight (Q3 2020: 1,21 EUR per kilo live weight slaughter pigs) with 1.880 kEUR positive effect.



## Statement by the Board and the Executive Management

The Executive Board and the Board of Directors have presented the interim Report of Idavang A/S. The interim Report has today been considered and adopted.

The Interim Report, which has not been audited or reviewed by the Company's independent auditors, was prepared in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for listed companies.

In our opinion, the Interim Financial Statements give a true and fair view of the financial position of the Group at 30th September 2021 as well as of the results of the Group operations and cash flows for the period 1st Jan – 30th September 2021.


In our opinion, Management's Review gives a true and fair account of the development in the activities and financial circumstances of the Group, of results of operations for the period and of the overall financial position of the Group, and a description of the key risks and uncertainties facing the Group.

### Executive Management

Claus Baltzersen  
CEO



Michael Thuesen Henriksen  
CFO



### Board of Directors

Niels Hermansen  
Chairman



Claus Baltzersen



Jytte Rosenmaj



Ole B. Hansen



Carsten Lund Thomsen





## Financial Statement

### *Income Statement*

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Revenue	26.703	24.728	79.769	79.284	101.754
Value adjustment, biological assets	-4.899	-3.821	2.397	-5.142	-9.264
Production costs	-21.225	-18.851	-69.483	-64.664	-88.616
Administrative costs	-908	-893	-2.646	-2.675	-3.457
Other income	1.621	495	2.497	1.782	2.436
Other expense	-507	-10	-192	-62	-72
<b>Operating profit</b>	<b>786</b>	<b>1.648</b>	<b>12.340</b>	<b>8.522</b>	<b>2.781</b>
Net Financials	-1.664	-1.389	-4.848	-4.123	-7.683
Foreign exchange adjustments	125	-2.238	591	-4.047	-3.541
<b>Profit before tax</b>	<b>-753</b>	<b>-1.980</b>	<b>8.084</b>	<b>351</b>	<b>-8.443</b>
Tax on profit for the year	707	504	-185	-68	682
<b>Profit for the period</b>	<b>-46</b>	<b>-1.477</b>	<b>7.899</b>	<b>283</b>	<b>-7.761</b>
EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Depreciations included in production cost	-1.851	-1.785	-5.454	-5.594	-7.699
<b>EBITDA</b>	<b>2.637</b>	<b>3.432</b>	<b>17.794</b>	<b>14.115</b>	<b>10.480</b>
<i>EBITDA fixed herd prices</i>	<i>7.536</i>	<i>7.253</i>	<i>15.398</i>	<i>19.258</i>	<i>19.744</i>

### *Statement of comprehensive income*

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Profit for the period	-46	-1.477	7.899	283	-7.761
<b>Other comprehensive income</b>					
Exchange adjustments, foreign subsidiaries	1.180	-7.912	3.421	-13.823	-12.349
Hedge accounting	2.460	254	3.471	403	535
<b>Other comprehensive income to be reclassified to profit or loss in subsequent periods</b>	<b>3.640</b>	<b>-7.658</b>	<b>6.892</b>	<b>-13.420</b>	<b>-11.814</b>
Other comprehensive income not to be reclassified to profit or loss in subsequent periods	-	-	-	-	-
<b>Total comprehensive income</b>	<b>3.594</b>	<b>-9.135</b>	<b>14.791</b>	<b>-13.137</b>	<b>-19.575</b>

## Assets

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Intangible assets	1.227	1.229	1.227	1.229	1.226
Property, Plant and Equipment	79.800	79.509	79.800	79.509	79.451
Biological Assets, Breeding herd	12.023	16.033	12.023	16.033	15.469
Deferred tax	760	757	760	757	760
Financial fixed assets	446	450	446	450	446
<b>Total non-current assets</b>	<b>94.257</b>	<b>97.979</b>	<b>94.257</b>	<b>97.979</b>	<b>97.353</b>
Inventories	16.183	12.383	16.183	12.383	12.195
Biological Assets, Commercial herd	17.144	20.165	17.144	20.165	17.116
Biological Assets, Arable	634	611	634	611	1.099
<b>Biological Assets</b>	<b>17.779</b>	<b>20.776</b>	<b>17.779</b>	<b>20.776</b>	<b>18.215</b>
Trade receivables	5.036	1.195	5.036	1.195	3.369
Other receivables	8.608	403	8.608	403	429
Prepayments	665	838	665	838	901
Income taxes receivables	-	-	-	-	-
<b>Receivables</b>	<b>14.309</b>	<b>2.436</b>	<b>14.309</b>	<b>2.436</b>	<b>4.699</b>
Assets held for sale	-	-	-	-	-
Cash	7.434	33.818	7.434	33.818	13.757
<b>Total current assets</b>	<b>55.706</b>	<b>69.414</b>	<b>55.706</b>	<b>69.414</b>	<b>48.867</b>
<b>Total Assets</b>	<b>149.962</b>	<b>167.393</b>	<b>149.962</b>	<b>167.393</b>	<b>146.219</b>

## Liabilities and Equity

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Share capital	800	1.000	800	1.000	800
Exchange adjustments	-35.156	-40.051	-35.156	-40.051	-38.577
Other reserves	4.017	415	4.017	415	547
Retained earnings	74.997	92.847	74.997	92.847	67.098
<b>Equity</b>	<b>44.658</b>	<b>54.211</b>	<b>44.658</b>	<b>54.211</b>	<b>29.868</b>
Borrowings	72.742	81.974	72.742	81.974	80.282
Grants	1.558	1.636	1.558	1.636	1.598
Deferred tax	1.625	1.819	1.625	1.819	1.519
Provisions	-	134	-	134	-
Other non-current liabilities	810	39	810	39	39
<b>Non current liabilities</b>	<b>76.734</b>	<b>85.602</b>	<b>76.734</b>	<b>85.602</b>	<b>83.437</b>
Borrowings	17.792	16.289	17.792	16.289	21.268
Trade payables	7.823	8.269	7.823	8.269	8.396
Income taxes payables	-212	1.083	-212	1.083	559
Other payables	3.167	1.938	3.167	1.938	2.841
<b>Current liabilities</b>	<b>28.569</b>	<b>27.579</b>	<b>28.569</b>	<b>27.579</b>	<b>33.064</b>
<b>Total liabilities</b>	<b>105.303</b>	<b>113.181</b>	<b>105.303</b>	<b>113.181</b>	<b>116.501</b>
<b>Total Equity and Liabilities</b>	<b>149.962</b>	<b>167.392</b>	<b>149.962</b>	<b>167.393</b>	<b>146.369</b>

## Cash Flow Statement

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
Operating profit/loss	786	1.648	12.340	8.522	2.782
Adjustment for non-cash operating items	9.210	5.860	6.528	11.139	17.344
	9.996	7.507	18.869	19.661	20.126
Change in working capital incl. herd	- 8.240	- 3.126	- 8.568	8.142	8.472
<b>Cash flow from ordinary activities before financials</b>	<b>1.757</b>	<b>4.382</b>	<b>10.300</b>	<b>27.803</b>	<b>28.598</b>
Net financials	- 1.664	1.389	- 4.848	4.085	-
Corporate tax paid	- 415	128	- 79	115	39
<b>Cash flow from ordinary activities</b>	<b>- 323</b>	<b>3.120</b>	<b>5.373</b>	<b>23.833</b>	<b>28.637</b>
<b>Cash flow from investing activities</b>	<b>1.298</b>	<b>- 739</b>	<b>318</b>	<b>- 2.751</b>	<b>- 4.217</b>
Proceeds from borrowings	3.460	1.887	12.666	7.288	88.578
Repayments of borrowings	- 9.070	- 3.391	- 24.785	- 22.650	- 101.296
Dividends paid to shareholders	-	-	-	-	-
Surplus on Escrow account	-	-	-	-	6.722
<b>Cash flow from financing activities</b>	<b>- 5.611</b>	<b>- 1.504</b>	<b>- 12.119</b>	<b>- 15.362</b>	<b>- 5.996</b>
Cash and cash equivalents primo priod	11.777	9.888	13.757	5.524	5.524
Change in cash and cash equivalents	- 4.635	877	- 7.064	5.721	11.555
Exchange adjustments	292	- 1.672	741	- 2.150	- 3.322
<b>Cash and cash equivalents end priod</b>	<b>7.433</b>	<b>9.094</b>	<b>7.433</b>	<b>9.094</b>	<b>13.757</b>

The group furthermore has 11.400 kEUR overdraft facilities not utilized at period-end (partly Jyske Bank and partly Raiffeisen Bank, Russia) and own 3.700 kEUR Idavang Bonds.

## Statement of changes in equity

EUR '000	Share capital	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2021	800	- 38.577	547	67.098	29.868
Profit/Loss for the period				7.899	7.899
Other comprehensive income		3.421	3.471		6.892
Total comprehensive income	-	3.421	3.471	7.899	14.791
Equity at 30th September 2021	800	- 35.156	4.018	74.997	44.659

EUR '000	Share capital	Exchange adjustment	Other reserves	Retained earnings	Total
Equity at 1st January 2020	1.000	- 26.228	12	92.564	67.348
Profit/Loss for the period				- 7.761	- 7.761
Other comprehensive income		- 12.349	535		- 11.814
Total comprehensive income	-	- 12.349	535	- 7.761	- 19.575
Dividend					-
Repurchase shares	- 200			- 17.705	- 17.905
Equity at 31st December 2020	800	- 38.577	547	67.098	29.868



## Notes

### Note 1 Basis of preparation and changes to the Group's accounting policies

The interim condensed consolidated financial statements for the 9 months ended 30th September 2021 have been prepared in accordance with Idavang A/S' accounting policies as stated in the latest financial statements for the company and in accordance with IAS 34 "Interim Financial Reporting" as adopted by the EU and additional Danish disclosure requirements for interim financial reporting of listed companies.

The consolidated financial statements are presented in thousand EUR.

The Interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as at 31st Dec 2020.

The Group's accounting policies is unchanged compared with the Group's annual financial statements as at 31st Dec 2020.

### Note 2 Biological assets measured at fair value

The change in the value of biological assets for Q3 2021 is stated in the below table. The total change in fair value is included in revenue reported in the income statement.

EUR '000	Q3 2021	Q3 2020	9M 2021	9M 2020	2020
<b>Commercial herd primo</b>	25.493	25.381	17.116	27.662	27.662
Change in fair value	-8.966	-3.628	-662	-4.755	-8.197
Exchange adjustments	617	-1.588	690	-2.742	-2.349
<b>Commercial herd ultimo</b>	<b>17.144</b>	<b>20.165</b>	<b>17.144</b>	<b>20.165</b>	<b>17.116</b>
<b>Breeding herd primo</b>	14.554	16.101	15.469	15.772	15.772
Change in fair value	-2.524	1.180	-3.742	2.396	1.551
Exchange adjustments	-7	-1.248	296	-2.135	-1.854
<b>Breeding herd ultimo</b>	<b>12.023</b>	<b>16.033</b>	<b>12.023</b>	<b>16.033</b>	<b>15.469</b>
<b>Herd total primo</b>	40.048	41.482	32.585	43.434	43.434
Change in fair value due to volume	-6.591	1.373	-6.800	2.784	2.617
Change in fair value due to price	-4.899	-3.821	2.397	-5.142	-9.263
Exchange adjustments	610	-2.837	986	-4.878	-4.203
<b>Herd total ultimo</b>	<b>29.168</b>	<b>36.198</b>	<b>29.168</b>	<b>36.198</b>	<b>32.585</b>
<b>Crop primo</b>	3.053	3.154	1.099	1.589	1.589
Change in fair value due to volume	-2.336	-2.477	-309	-608	-128
Change in fair value due to price	-	-	-	-	-
Exchange adjustments	-84	-66	-155	-370	-362
<b>Crop ultimo</b>	<b>634</b>	<b>611</b>	<b>634</b>	<b>611</b>	<b>1.099</b>
<b>Total Biological Assets primo</b>	43.101	44.636	33.684	45.023	45.023
Change in fair value due to volume	-8.927	-1.104	-7.110	2.176	2.489
Change in fair value due to price	-4.899	-3.821	2.397	-5.142	-9.263
Exchange adjustments	526	-2.903	831	-5.248	-4.565
<b>Total Biological Assets ultimo</b>	<b>29.801</b>	<b>36.809</b>	<b>29.802</b>	<b>36.809</b>	<b>33.684</b>

### Note 3 Segment reporting

The group's results break down as follows on segments:

EUR '000	Q3 2021			
	Lithuania	Russia	Other / Eliminations	Group
Revenue	13.728	12.975	-	26.703
Value adjustment, biological assets	- 4.359	- 540	-	- 4.899
Production costs	- 14.820	- 6.405	-	- 21.225
Administrative costs	- 425	- 377	- 98	- 901
Other income	1.129	492	-	1.621
Other expense	11	- 518	- 7	- 514
<b>Operating profit</b>	<b>- 4.736</b>	<b>5.627</b>	<b>- 105</b>	<b>786</b>
Net Financials	- 292	- 399	- 973	- 1.664
Foreign exchange adjustments	-	18	107	125
<b>Profit before tax</b>	<b>- 5.028</b>	<b>5.247</b>	<b>- 972</b>	<b>- 753</b>
Tax on profit for the year	745	- 38	-	707
<b>Profit for the period</b>	<b>- 4.284</b>	<b>5.209</b>	<b>- 972</b>	<b>- 46</b>

EUR '000				
Depreciations included in production cost	- 714	- 1.138	-	- 1.851
<b>EBITDA</b>	<b>- 4.023</b>	<b>6.765</b>	<b>- 105</b>	<b>2.637</b>
<i>EBITDA fixed herd prices</i>	<i>337</i>	<i>7.305</i>	<i>- 105</i>	<i>7.536</i>

EUR '000	Q3 2020			
	Lithuania	Russia	Other / Eliminations	Group
Revenue	13.396	11.331	-	24.728
Value adjustment, biological assets	- 4.092	271	-	- 3.821
Production costs	- 12.879	- 5.972	-	- 18.851
Administrative costs	- 429	- 274	- 190	- 893
Other income	458	38	-	495
Other expense	-	10	-	10
<b>Operating profit</b>	<b>- 3.545</b>	<b>5.383</b>	<b>- 190</b>	<b>1.648</b>
Net Financials	- 208	- 350	- 832	- 1.389
Foreign exchange adjustments	-	- 158	- 2.080	- 2.238
<b>Profit before tax</b>	<b>- 3.753</b>	<b>4.875</b>	<b>- 3.102</b>	<b>- 1.980</b>
Tax on profit for the year	502	2	-	504
<b>Profit for the period</b>	<b>- 3.251</b>	<b>4.877</b>	<b>- 3.102</b>	<b>- 1.477</b>

EUR '000				
Depreciations included in production cost	- 761	- 1.023	-	- 1.785
<b>EBITDA</b>	<b>- 2.784</b>	<b>6.406</b>	<b>- 190</b>	<b>3.432</b>
<i>EBITDA fixed herd prices</i>	<i>1.309</i>	<i>6.135</i>	<i>- 190</i>	<i>7.253</i>

EUR '000	9M 2021			
	Lithuania	Russia	Other / Eliminations	Group
Revenue	42.180	37.588	-	79.769
Value adjustment, biological assets	710	1.686	-	2.397
Production costs	- 42.050	- 27.433	-	- 69.483
Administrative costs	- 1.317	- 963	- 367	- 2.646
Other income	1.770	726	-	2.497
Other expense	333	- 518	- 7	- 192
<b>Operating profit</b>	<b>1.627</b>	<b>11.087</b>	<b>- 374</b>	<b>12.340</b>
Net Financials	- 897	- 1.061	- 2.891	- 4.848
Foreign exchange adjustments	-	- 15	607	591
<b>Profit before tax</b>	<b>731</b>	<b>10.011</b>	<b>- 2.658</b>	<b>8.084</b>
Tax on profit for the year	- 123	- 62	-	- 185
<b>Profit for the period</b>	<b>608</b>	<b>9.949</b>	<b>- 2.658</b>	<b>7.899</b>

EUR '000				
Depreciations included in production cost	- 2.196	- 3.257	-	- 5.454
<b>EBITDA</b>	<b>3.824</b>	<b>14.345</b>	<b>- 374</b>	<b>17.794</b>
<i>EBITDA fixed herd prices</i>	<i>3.113</i>	<i>12.658</i>	<i>- 374</i>	<i>15.398</i>

EUR '000	9M 2020			
	Lithuania	Russia	Other / Eliminations	Group
Revenue	48.237	31.046	-	79.284
Value adjustment, biological assets	- 8.332	3.190	-	- 5.142
Production costs	- 39.255	- 25.405	- 4	- 64.664
Administrative costs	- 1.325	- 869	- 482	- 2.675
Other income	1.407	375	-	1.782
Other expense	- 2	- 53	- 7	- 62
<b>Operating profit</b>	<b>730</b>	<b>8.284</b>	<b>- 493</b>	<b>8.522</b>
Net Financials	- 698	- 1.053	- 2.372	- 4.123
Foreign exchange adjustments	-	- 229	- 3.818	- 4.047
<b>Profit before tax</b>	<b>32</b>	<b>7.003</b>	<b>- 6.684</b>	<b>351</b>
Tax on profit for the year	- 24	- 44	-	- 68
<b>Profit for the period</b>	<b>8</b>	<b>6.958</b>	<b>- 6.684</b>	<b>283</b>

EUR '000				
Depreciations included in production cost	- 2.226	- 3.364	- 4	- 5.594
<b>EBITDA</b>	<b>2.956</b>	<b>11.649</b>	<b>- 489</b>	<b>14.115</b>
<i>EBITDA fixed herd prices</i>	<i>11.288</i>	<i>8.459</i>	<i>- 489</i>	<i>19.258</i>

EUR '000	2020				Group
	Lithuania	Russia	Other / Eliminations		
Revenue	60.551	41.203	-	-	101.754
Value adjustment, biological assets	- 11.270	2.006	-	-	- 9.264
Production costs	- 53.098	- 35.516	-	2	- 88.616
Administrative costs	- 1.844	- 1.038	-	574	- 3.457
Other income	1.615	821	-	-	2.436
Other expense	2	- 67	-	7	- 72
<b>Operating profit</b>	<b>- 4.044</b>	<b>7.409</b>	<b>- 584</b>		<b>2.781</b>
Net Financials	- 1.056	- 1.444	-	5.183	- 7.683
Foreign exchange adjustments	-	- 128	-	3.413	- 3.541
<b>Profit before tax</b>	<b>- 5.100</b>	<b>5.837</b>	<b>- 9.180</b>		<b>8.443</b>
Tax on profit for the year	765	- 83	-	-	682
<b>Profit for the period</b>	<b>- 4.335</b>	<b>5.754</b>	<b>- 9.180</b>		<b>7.761</b>
<hr/>					
EUR '000					
Depreciations included in production cost	- 3.182	- 4.514	-	2	- 7.699
<b>EBITDA</b>	<b>- 862</b>	<b>11.923</b>	<b>- 581</b>		<b>10.480</b>
<i>EBITDA fixed herd prices</i>	<i>10.408</i>	<i>9.917</i>	<i>- 581</i>		<i>19.744</i>



## Note 4 Summary of bond terms

<b>Issuer</b>	Idavang A/S
<b>Security package:</b>	(i) share pledges over Guarantors and Russian operating companies, (ii) mortgages over substantially Lithuanian real estate, (iii) Danish registered negative pledges, (iv) account pledge over IFC Deposit account and (v) assignment over intra-group loan (RUB 0.91bn) from the Issuer to Idavang Agro LLC
<b>Original Guarantors:</b>	Rus Invest Aps, Rurik A/S, Pskov Invest Aps, Idavang Russia A/S, UAB Idavang
<b>Status of the bond:</b>	Senior secured
<b>Currency:</b>	EUR
<b>Initial debt amount:</b>	EUR 75 millions
<b>Other facilities:</b>	Super senior RCF up to 9 mEUR, governed under an inter-creditor
<b>Tenor</b>	5 years
<b>Pricing:</b>	3m EURIBOR + 725 bps p.a., quarterly interest payments, EURIBOR floor of 0.0%
<b>Rating:</b>	Unrated
<b>Call options:</b>	Non call during the first 30 months, then 50/33/25/10/0 after 30/36/42/48/57
<b>Incurrence test</b>	Cash sweep of 50% of Free cash flow at 102.3925, starting from NIBD/EBITDA LTM fixed herd price (net leverage) of 3.00 and No
<b>Restricted payments</b>	No financial support (by way of loans, capital or similar) by the Issuer to Russian subsidiaries, except if funded by the super senior facility or if the incurrence test is met (excluding the IFC Deposit from Net Interest Bearing Debt)
<b>Information covenants:</b>	Annual audited statements, quarterly unaudited reports
<b>Change of control:</b>	Investor put at 101%
<b>Listing of bonds:</b>	Nasdaq Copenhagen
<b>Trustee:</b>	Nordic Trustee
<b>Governing law:</b>	Danish law

## Quarterly Financial Highlights and Key Ratios

EUR '000	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020
<b>Income statement</b>						
Revenue	26.703	28.305	24.760	22.471	24.728	25.826
EBITDA	2.637	3.667	11.490	- 3.635	3.432	- 2.666
EBITDA fixed herd price	7.536	6.111	1.750	486	7.253	4.754
EBIT	786	1.836	9.718	- 5.740	1.648	- 4.546
Financial items, net	- 1.539	- 1.285	- 1.433	- 3.054	- 3.628	- 387
Profit/(loss) for the period	- 46	543	7.401	- 8.044	- 1.477	- 4.728
<b>Cash flow</b>						
Operating activity	- 323	5.136	560	- 2.065	3.120	7.236
Investing activity	1.298	- 1.686	70	- 1.466	- 739	- 1.104
Financing activity	- 5.611	- 2.446	- 4.062	9.366	- 1.504	- 7.450
Free cash flow	2.640	4.735	2.528	- 748	3.771	7.695
<b>Balance sheet</b>						
Non-current assets	94.257	96.811	96.497	97.353	97.979	106.656
Net working capital	20.501	22.230	22.709	11.079	11.883	20.567
Net operating assets	114.758	119.041	119.206	108.432	109.862	127.224
Total assets	149.962	155.033	152.206	146.369	167.393	182.406
Equity	44.658	41.065	38.231	29.867	54.211	63.346
Net interest bearing debt	82.653	83.800	86.688	87.346	63.995	68.340
<b>Key financials Group</b>						
EBITDA margin	9,9%	13,0%	46,4%	-16,2%	13,9%	-10,3%
EBITDA margin - fixed herd prices	28,2%	21,6%	7,1%	2,2%	29,3%	18,4%
Cash conversion	35,0%	77,5%	144,5%	-153,8%	52,0%	161,9%
NIBD / EBITDA fixed price LTM	5,2	5,4	6,1	4,4	2,5	2,5
Equity ratio	29,8%	26,5%	25,1%	20,4%	32,4%	34,7%

## Appendix / Production information

### Idavang Group

	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020
<b>Number of Sows average</b>						
Lithuania	15.104	15.180	15.247	15.344	15.170	15.125
Russia	9.124	10.194	10.314	10.335	10.410	10.474
Total	24.228	25.374	25.561	25.679	25.580	25.599

### Pigs sold (slaughterpigs, Weaners and Sows)

Lithuania	119.534	119.392	119.931	125.688	113.213	118.357
Russia	80.074	87.681	89.239	85.836	81.760	79.440
Total	199.608	207.073	209.170	211.524	194.973	197.797

### Displacement

Lithuania	710	262	619	- 4.177	7.784	3.101
Russia	- 2.832	- 3.583	- 4.128	- 472	5.427	10.254
Total	- 2.122	- 3.321	- 3.509	- 4.649	13.211	13.355
Russia, Ostrov	- 53.489					

### Total production

Lithuania	120.244	119.654	120.550	121.511	120.997	121.458
Russia	77.242	84.098	85.111	85.364	87.187	89.694
Total	197.486	203.752	205.661	206.875	208.184	211.152

### Feed cost kEUR

Lithuania	- 10.136	- 9.326	- 8.798	- 8.952	- 9.118	- 8.952
Russia	- 6.911	- 6.882	- 7.123	- 6.934	- 6.600	- 6.597
Total	- 17.048	- 16.208	- 15.921	- 15.886	- 15.718	- 15.549

### Feed conversion kg/kg

	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020
Lithuania	2,88	2,81	2,79	2,78	2,83	2,81
Russia	2,89	2,82	2,99	2,96	2,85	2,91
Group	2,89	2,81	2,87	2,86	2,84	2,85